U.S. Congress Approves $2 Billion Increase for NIH Funding

Posted by: Nikki Meadows, PhD, ASHG/NHGRI Genetics & Public Policy Fellow

Last month, the U.S. Congress approved legislation establishing a $2 billion (or 5.1%) funding increase for the National Institutes of Health (NIH) in Fiscal Year (FY) 2019. NIH’s total funding for FY 2019 is $39.1 billion. This includes increased funding for several priority research initiatives, such as the Cancer Moonshot and the All of Us research Initiative.

Increase Will Support New Priorities in Genetics and Genomics

The legislation (H.R. 6157) was signed into law by President Trump on September 28, after passing both the Senate (93-7) and the House (361-61). The $2 billion boost is the fourth consecutive increase in the NIH budget in recent years, demonstrating strong bipartisan support for biomedical research in Congress. Significantly, it is the first time in over 20 years that Congress has finalized the NIH budget on time.

The $2 billion increase is consistent with the increase recommended and advocated for by ASHG and other FASEB organizations. (Credit: NIH Research Funding Trends, FASEB)

In addition to Congress being able to allocate funding for specific research initiatives, the annual appropriations bill also gives Congress an opportunity to issue directives to federal agencies, such as establishing how an agency should proceed on a particular activity or commissioning a report about a particular topic. One such directive you may be familiar with is the so-called “Dickey-Wicker Amendment,” which forbids the use of federal research dollars on any research that harms human embryos. In the FY 2019 appropriations, there are three directives related to genetics and genomics:

  • Representatives Marcy Kaptur (D-OH) and Katherine Clark (D-MA) advanced an amendment protecting the genetic privacy of individuals seeking family reunification. The amendment directs the Office of Refugee Resettlement to ensure the protection and privacy of genetic material, data, or information of children, parents, and all of the individuals being tested and their relatives.
  • A Government Accountability Office report was commissioned to analyze the medical genetics workforce nationwide. The report is asked to determine whether there are a sufficient number of qualified professionals to serve this growing health need and whether there are any geographic areas that lack access to genetic counseling professionals.
  • An amendment from Senator Marco Rubio (R-FL) requires the HHS Secretary to submit a report on the circumstances in which the Centers for Medicare and Medicaid Services may be providing payments to, or otherwise funding, entities that process genome or exome data in the People’s Republic of China or the Russian Federation.

Funding Bill’s Timely Passage Will Help with Long-Term Planning

The fiscal year runs from October 1 through September 30 of the following year, and each year, Congress is required to establish funding for upcoming fiscal year. For the past 21 years, Congress has missed the deadline, and in order to avoid a government shutdown, had to pass a Continuing Resolution (CR) that agreed to continue to fund the government until a new spending bill was completed. Indeed, such a scenario caused brief shutdowns last winter.

This year, the Department of Health and Human Services, which includes NIH, was funded through all of FY 2019, so there is no possibility of a shutdown for NIH. The budget’s timely passage means that institutes and centers can plan for the year ahead knowing what funds are available. However, other agencies, including the National Science Foundation, are currently funded by a CR until December 7, 2018, and funding for these agencies in FY 2019 remains uncertain.

Inside AJHG: A Chat with Hugo Bellen and Julia Wang

Posted by: Sara Cullinan, Deputy Editor, AJHG

Each month, the editors of The American Journal of Human Genetics interview an author of a recently published paper. This month, we check in with Hugo Bellen, DVN, PhD, and his student Julia Wang, two of the co-authors of “MARRVEL: Integration of Human and Model Organism Genetic Resources to Facilitate Functional Annotation of the Human Genome.”

Zhandong Liu, PhD (left); Julia Wang (center); and Hugo Bellen, DVM, PhD (right). (courtesy Dr. Bellen)

AJHG: How did you begin working on this project?

Hugo and Julia: As the Model Organism Screening Center for the Undiagnosed Diseases Network (UDN), we receive cases from the UDN clinical sites to assess if variants of unknown significance or variants in genes that have not yet been associated with human diseases might affect protein function. Our goal is to functionally test variants in fruit fly or zebrafish homologues. This project began because of our need to efficiently identify the best human candidate variants of those submitted by the clinical sites for a specific human disease. As each gene and variant requires a substantial amount of work, we need to be as selective as possible and mine as much information as possible before making a decision. We therefore screen public human and model organism databases to systematically extract information that may guide our project and selection. We developed MARRVEL to gather all this information and help us in the selection of the best candidates for further analysis.

AJHG: What about this paper most excites you?

Hugo and Julia: The ability to immediately obtain key information such as allele frequency in different human populations, human gene function, phenotypes, and expression and function of homologues of the human gene in all model organisms. Through MARRVEL, the accessibility of human genetics and model organism data is greatly facilitated. As of mid-June, we have about a thousand returning users spanning the USA, Europe, Asia, Australia, and beyond.

AJHG: Thinking about the bigger picture, what implications do you see from this work for the larger human genetics community?

Hugo and Julia: We foresee that model organisms will play a progressively more important role in human genetics in the future. By providing human geneticists with an approachable gateway to model organism research, and vice versa, MARRVEL will likely increase collaboration between human geneticists and model organism researchers at a critical point. Indeed, in a few years, the vast majority of genes that cause disease will have been identified. We will then have to focus on the mechanisms by which these genes cause disease. This can best be done in model organisms like worms, flies, and zebrafish as nothing can replace whole organisms in the quest for mechanisms and development of drugs. In our lab, we have successfully used fruit flies to better understand the pathogenic mechanisms associated with Parkinson’s disease, Alzheimer’s disease, Friedreich’s ataxia, and others. We anticipate that discovering mechanisms associated with loss and gain of gene function implicated in rare diseases will tell us heaps about common disease and how to tackle some problems in patients.

AJHG: What advice do you have for trainees/young scientists?

Hugo: The model organisms, such as yeast, worms, flies, fish and mice, provide us with the necessary sophisticated tools to tackle many probing questions related to human pathobiology and drive discovery. Note that of the 106 Nobel prices in Physiology and Medicine, 94 were dependent on animal model systems. This includes every prize for the past 30 years. I anticipate that many more will follow as our model organisms allow us to develop superb tools like monoclonal Ab, RNAi, and CRISPR, as well as many elegant genetic tools to manipulate their genomes. Hence, we will continue to break the code of human life and disease. If I were a young scientist, I would again embark on a career in genetic research in yeast, worms, or flies with more emphasis on the integration of the acquired knowledge with human biology.

AJHG: And for fun, tell us something about your life outside of the lab.

Hugo: I love fishing and especially fly fishing. In a nutshell, flies rule my work and hobby.  Unfortunately, the hobby part is restricted to less than 0.5% of my available time.

Hugo Bellen, DVM, PhD, is a Professor in the Departments of Molecular & Human Genetics and Neuroscience as well as the Program in Developmental Biology, and an Investigator of the Howard Hughes Medical Institute, at the Baylor College of Medicine.


Inside AJHG: A Chat with Eleazar Eskin

Posted by: Sara Cullinan, Deputy Editor, AJHG

Each month, the editors of The American Journal of Human Genetics interview an author of a recently published paper. This month, we checked in with Eleazar Eskin, PhD, former AJHG editorial board member and senior author of “Widespread Allelic Heterogeneity in Complex Traits”.

Eleazar Eskin, PhD
Eleazar Eskin, PhD, and recent ZarLab graduate Farhad Hormozdiari, PhD. (courtesy Dr. Eskin)

AJHG: How did you begin working on this project? 

Eleazar: This project originated when we observed a surprising result in a previous study, which was also published in AJHG. In our paper, “Colocalization of GWAS and eQTL Signals Detects Target Genes,” published in the December 2016 issue, we observed that for many loci which had both an observed expression quantitative loci (eQTL) signal as well as a GWAS signal, the actual variant responsible for these signals was different in the two studies. This was very surprising and was counter to the intuition of the field. We conjectured that what was going on was that many of the eQTL loci had multiple causal variants, referred to as allelic heterogeneity, and what could explain the observation is that the variants we are observing in the eQTL studies are only some of the variants affecting expression.

AJHG: What about this paper most excites you? 

Eleazar: The method that we developed can identify alleleic heterogeneity even when we can’t pinpoint the actual causal variants. We also showed that alleleic heterogeneity is very prevalent; the primary reason we haven’t been able to detect if more frequently is that our studies are under-powered.

AJHG: Thinking about the bigger picture, what implications do you see from this work for the larger human genetics community?

Eleazar: Our study suggests that many variants are affecting each locus. Our result informs attempts to understand the mechanism underlying GWAS loci by providing a better understanding of how variants affect expression. In addition, this study helps us understand why we have, to date, been unable to detect colocalization of many GWAS and eQTL variants.

AJHG: What advice do you have for trainees/young scientists?

Eleazar: My main advice is to write up your research quickly. So much time is spent inefficiently in the writing process. On my lab website, zarlab.cs.ucla.edu, I have a series of blog posts with writing tips to help young scientists get their research published faster.

AJHG: And for fun, tell us something about your life outside of the lab.

Eleazar: I love to cook using traditional ethnic ingredients. I also love training for triathlons.

Eleazar Eskin, PhD, is a Professor of Computer Science and Human Genetics at UCLA. He has been a member of ASHG since 2006.